All In Biotech

Investigational drug · Phase 3

Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Anti IL-6R, Idiopathic Multicentric Castleman's Disease, Castleman's Disease, Multicentric.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

8

Any phase or sponsor naming "Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody"

First trial start

2022

Apr 18, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Anti IL-6R
  • Idiopathic Multicentric Castleman's Disease
  • Castleman's Disease, Multicentric
  • Rheumatoid Arthritis (RA)

Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.